NY-SULLIVAN-&-CROMWELL
3.1.2022 15:48:09 CET | Business Wire | Press release
Sullivan & Cromwell LLP announced today that Robert J. Giuffra, Jr. and Scott Miller have become Co-Chairs of the firm, effective January 1, 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220103005204/en/
Mr. Giuffra and Mr. Miller have served as Vice Chairs of the firm since January 2021. They succeed Joseph C. Shenker, the firm’s Chair since 2010, who will continue to serve on the firm’s Management Committee as Senior Chair in addition to continuing with his active client practice.
“Since the days of our founders, Sullivan & Cromwell has an unwavering commitment to our clients, our people and our communities,” said Mr. Shenker. “Bob and Scott exemplify these qualities, long ago establishing themselves as trusted counselors whose complementary strengths in litigation and corporate law reflect the broad scope of work we do for our clients around the world.”
“Our firm’s international practice and ability to deliver integrated client service through our network of 13 offices across four continents are critical to our success,” said Mr. Miller. “More than half of our firm’s clients are headquartered outside the United States, and Bob and I have each spent our careers handling our clients’ most complex cross-border matters. As the world becomes even more integrated and the issues clients face become more complex, we expect our global practice to be a driver of our firm’s continued success.”
“I am honored to work with Scott and our partners to build on our firm’s strong culture of excellence, innovation and commitment to our clients and each other,” said Mr. Giuffra. “For 143 years, our model has been tried and true: to recruit and train the best lawyers to work together to help our clients solve their most critical challenges and capture their highest value opportunities.”
Mr. Giuffra, a nationally prominent litigator, joined S&C in 1989 after serving as a law clerk to Chief Justice William Rehnquist of the U.S. Supreme Court and Judge Ralph Winter of the U.S. Court of Appeals for the Second Circuit. Based in New York, he has been a member of Sullivan & Cromwell’s Management Committee since 2007. A fellow of the American College of Trial Lawyers and International Academy of Trial Lawyers, he has successfully represented the firm’s clients in multi-billion dollar trials, litigations and government investigations. He has played a significant role in navigating some of the biggest corporate crises of the past 20 years, including the bankruptcy of Enron, the accounting frauds at Computer Associates and HealthSouth Corporation, the financial crisis, and the Volkswagen diesel emissions crisis for which he served as the carmaker’s national coordinating counsel. His current clients include Allianz, Goldman Sachs, Stellantis, UBS and Volkswagen. He has represented corporate boards and directors, CEOs, senior public officials, prominent families, law firms and professional sports teams.
Mr. Miller, a premier corporate counselor, joined S&C in 1986 after serving as a law clerk to Judge William A. Norris of the U.S. Court of Appeals for the Ninth Circuit. He routinely handles multi-billion dollar M&A, capital markets and other strategic transactions, internal and government investigations and other corporate crises. Now based in New York, he has been a member of the Firm’s Management Committee since 2014 and coordinates our U.S. and European corporate practices. He has worked on M&A and securities transactions in more than 20 countries, including the first privatization in Italy and the first German LBO. He represented Fiat Chrysler in its $60 billion merger with Peugeot, which transformed the global auto industry through the creation of Stellantis. Earlier, he represented Fiat in connection with its 2009 rescue of Chrysler, Ferrari in its 2015 IPO, and Alcan in fighting off a hostile takeover offer from Alcoa and in its $46 billion acquisition by Rio Tinto. He has represented DISH Network for two decades and recently in a series of transactions that helped it form and fund its nationwide wireless communications network. He has also recently been in the forefront of the SPAC market, representing among others DraftKings in its de-SPAC listing and other acquisitions and financings to create one of the world’s largest digital sports entertainment and gaming companies and Ermenegildo Zegna Group in its merger with a SPAC sponsored by Investindustrial through which Zegna became a NYSE-listed company, with an initial market capitalization in excess of $3 billion.
Mr. Giuffra is a graduate of Princeton University and Yale Law School. He has served as Chief Counsel of the U.S. Senate Banking Committee and as President of the Federal Bar Council. He is a member of New York’s Permanent Commission on Access to Justice and the Standing Committee on Rules of Practice and Procedure of the U.S. Courts. He is chair of the American Swiss Foundation.
Mr. Miller is a graduate of Arizona State University and Columbia Law School. He was managing partner of Sullivan & Cromwell’s Palo Alto office and has been resident in the firm’s London and Los Angeles offices. He is a trustee of the United States Council for International Business.
About Sullivan & Cromwell LLP
Sullivan & Cromwell LLP is a global law firm that advises on significant litigation, corporate investigations and complex regulatory, major domestic and cross-border M&A, finance, corporate and restructuring transactions, tax and estate planning matters. Founded in 1879, Sullivan & Cromwell has approximately 900 lawyers located in offices in New York, Washington, Los Angeles, Palo Alto, London, Frankfurt, Paris, Brussels, Hong Kong, Beijing, Tokyo, Melbourne and Sydney.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005204/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
